Spiriva is a brand name of tiotropium, approved by the FDA in the following formulation(s):
SPIRIVA (tiotropium bromide monohydrate - powder; inhalation)
Manufacturer: BOEHRINGER INGELHEIM
Approval date: January 30, 2004
Strength(s): EQ 0.018MG BASE/INH [RLD]
Has a generic version of Spiriva been approved?
No. There is currently no therapeutically equivalent version of Spiriva available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Spiriva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Powders for inhalation
Patent 5,478,578
Issued: December 26, 1995
Inventor(s): Arnold; Klaus & Grass; Peter & Knecht; Adolf & Roos; Robert & Sluke; Gerhard & Thieme; Herbet & Wenzel; Joachim
Assignee(s): Boehringer Ingelheim KG
In order to control and optimize the amount of inhalable active substance released when drugs are administered as inhalation powders, the invention calls for the use of auxiliaries consisting of mixtures of coarser particles (average particle size>20 .mu.m) and finer particles (average particle sizePatent expiration dates:
- December 26, 2012✓
- December 26, 2012
Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Patent 6,777,423
Issued: August 17, 2004
Inventor(s): Rolf; Banholzer & Peter; Sieger & Christian; Kulinna & Michael; Trunk & Manfred; Graulich & Peter; Specht & Helmut; Meissner & Andreas; Mathes
Assignee(s): Boehringer Ingelheim Pharma KG
Crystalline monohydrate of (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.Patent expiration dates:
- September 24, 2021✓✓
- September 24, 2021
Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Patent 6,908,928
Issued: June 21, 2005
Inventor(s): Banholzer; Rolf & Sieger; Peter & Kulinna; Christian & Trunk; Michael & Graulich; Manfred & Specht; Peter & Meissner; Helmut & Mathes; Andreas
Assignee(s): BI Pharma KG.
Crystalline monohydrate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.Patent expiration dates:
- September 24, 2021✓✓✓
- September 24, 2021✓✓✓
- September 24, 2021
Inhalable powder containing tiotropium
Patent 7,070,800
Issued: July 4, 2006
Inventor(s): Bechtold-Peters; Karoline & Walz; Michael & Boeck; Georg & Doerr; Rolf
Assignee(s): Boehringer Ingelheim Pharma KG
The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.Patent expiration dates:
- January 22, 2022✓✓
- January 22, 2022
Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Patent 7,309,707
Issued: December 18, 2007
Inventor(s): Bender; Helmut & Graebner; Hagen & Schindler; Konrad & Trunk; Michael & Walz; Michael
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
The invention relates to a crystalline micronisate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.Patent expiration dates:
- September 24, 2021✓✓
- September 24, 2021
Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Patent 7,642,268
Issued: January 5, 2010
Inventor(s): Bender; Helmut & Graebner; Hagen & Schindler; Konrad & Trunk; Michael & Walz; Michael
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
The invention relates to a crystalline micronisate of (1 α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.Patent expiration dates:
- September 24, 2021✓✓
- September 24, 2021
Dry powder inhaler
Patent 7,694,676
Issued: April 13, 2010
Inventor(s): Wachtel; Herbert
Assignee(s): Boehringer Ingelheim GmbH
An inhaler for inhaling powdered pharmaceutical compositions from capsules includes: a lower part; a plate which can be latched to the lower part and with which the lower part can be closed off; a capsule holder for receiving the capsules, this holder being adapted to be lowered into the lower part; a mouthpiece latchable to the plate; a lid which covers the mouthpiece in a closed position and latches it by means of a closure element, the lower part, the plate, the mouthpiece and the lid being hinged together by means of a single joint; and an actuating member which can be moved out a resting position and thereby interacts with at least one pin which can be made to pierce the capsule holder.Patent expiration dates:
- March 12, 2027✓
- March 12, 2027
Method for the administration of an anticholinergic by inhalation
Patent 8,022,082
Issued: September 20, 2011
Inventor(s): Zierenberg; Bernd
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG
An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 μm, and a method of administering an inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 μm to 500 μm, the method comprising actuating an inhaler a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L containing the inhalable powder.Patent expiration dates:
- January 19, 2026✓✓
- January 19, 2026
Process for preparing powder formulations
Patent RE38912
Issued: December 6, 2005
Inventor(s): Walz; Michael & Boeck; Georg
Assignee(s): Boehringer Ingelheim Pharma KG
The invention relates to a new process for producing powdered preparations for inhalation.Patent expiration dates:
- October 11, 2021✓
- October 11, 2021
Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Patent RE39820
Issued: September 4, 2007
Inventor(s): Banholzer; Rolf & Bauer; Rudolf & Reichl; Richard
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
Compounds of the formula of which, in exemplary compounds, the thienyl group is attached via the 2-position and; (a) A is 3α-(6β, 7β-epoxy)-tropanyl methobromide and R1 is 2-thienyl; (b) A is 3α-(6, 7dehydro)-tropanyl methobromide and R1 is 2-thienyl; (c) A is 3β-tropanyl methobromide and R1 is 2-thienyl; and, (d) A is 3α-(N-isopropyl)-nortropanyl methobromide and R1 is cyclopentyl. There are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.Patent expiration dates:
- January 30, 2018✓✓✓
- January 30, 2018
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- December 17, 2012 - PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
See also...
- Spiriva Consumer Information (Drugs.com)
- Spiriva HandiHaler Consumer Information (Wolters Kluwer)
- Spiriva Consumer Information (Cerner Multum)
- Spiriva Advanced Consumer Information (Micromedex)
- Spiriva Handihaler AHFS DI Monographs (ASHP)
- Tiotropium Consumer Information (Wolters Kluwer)
- Tiotropium inhalation Consumer Information (Cerner Multum)
- Tiotropium Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
- Tiotropium Bromide AHFS DI Monographs (ASHP)
No comments:
Post a Comment